新型采血装置减少急诊血培养污染的成本效益分析
该研究通过决策分析模型评估急诊常规使用初始标本转移装置(ISDD)采集血培养的临床与经济收益。在已使用快速诊断试验且基线污染率为6%的医院,ISDD使每份血培养总成本节省272美元(3%),直接成本节省28美元(5.4%)。成本主要驱动因素为基线污染率和阴性血培养患者的抗生素使用时长。
要点
- 急诊常规使用ISDD采集血培养相比传统方法具有成本效益。
- 基线污染率6%且使用快速诊断试验时,每份血培养总成本节省272美元(3%)。
- 直接成本节省28美元(5.4%),主要成本驱动为基线污染率和阴性血培养抗生素时长。
核心结论
- 急诊常规使用ISDD采集血培养相比传统方法具有成本效益,可减少血培养污染的临床与经济影响。
研究设计与样本
- 决策分析模型,从医院视角评估急诊常规使用ISDD的预期每患者成本节省(微生物学、药学和间接医院成本)。
- 概率成本来自已发表文献及对药学/微生物学人员的直接观察。
- 模型分别代表常规使用或不使用阳性血培养快速诊断试验(RDT)的医院。
主要发现
- 在已使用RDT且基线污染率为6%的医院,ISDD使用与每份血培养总医院成本节省272美元(3%)相关。
- 直接成本节省为每份血培养28美元(5.4%)。
- 成本主要驱动因素为基线污染率和阴性血培养患者的抗生素使用时长。
关键数值与推荐
- 基线污染率6%且使用RDT时,ISDD每份血培养总成本节省272美元(3%)。
- 直接成本节省每份血培养28美元(5.4%)。
临床怎么用
- 支持在急诊血培养采集时常规使用ISDD作为减少污染、改善微生物学、药学和医院间接影响的成本效益策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blood culture contamination results in increased hospital costs and exposure to antimicrobials. We evaluated the potential clinical and economic benefits of an initial specimen diversion device (ISDD) when routinely utilized for blood culture collection in the emergency department (ED) of a quaternary care medical center. A decision analysis model was created to identify the cost benefit of the use of the ISDD device in the ED. Probabilistic costs were determined from the published literature and the direct observation of pharmacy/microbiology staff. The primary outcome was the expected per-patient cost savings (microbiology, pharmacy, and indirect hospital costs) with the routine use of an ISDD from a hospital perspective. The indirect costs included those related to an increased hospital length of stay, additional procedures, adverse drug reactions, and hospital-acquired infections. Models were created to represent hospitals that routinely or do not routinely use rapid diagnostic tests (RDT) on positive blood cultures. The routine implementation of ISDD for blood culture collection in the ED was cost beneficial compared to conventional blood culture collection methods. When implemented in a hospital utilizing RDT with a baseline contamination rate of 6%, ISDD use was associated with a cost savings of $272 (3%) per blood culture in terms of overall hospital costs and $28 (5.4%) in direct-only costs. The main drivers of cost were baseline contamination rates and the duration of antibiotics given to patients with negative blood cultures. These findings support the routine use of ISDD during blood culture collection in the ED as a cost-beneficial strategy to reduce the clinical and economic impact of blood culture contamination in terms of microbiology, pharmacy, and wider indirect hospital impacts.
引用
- Skoglund E, Dempsey CJ, Chen H, et al. Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. J Clin Microbiol. 2019. PMID: 30355758. doi:10.1128/JCM.01015-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。